AMRN רווח צפוי Amarin Corp

Amarin Corporation plc (AMRN) has developed a unique cardiology product with a robust evidence base, although R&D is currently stagnating due to patent expirations. The projected financial outcome illustrates the trend of expected revenues, while the 0.00 metric confirms the current level. The issuer's financial stability relies on the global sales of Vascepa, a drug that reduces the risk of myocardial infarctions.
AMRN (Amarin Pharma): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Amarin Corporation plc (AMRN) investments in a high-paid staff of cardiology experts directly impact operating expenses, which is digitized in the current value of 0.00. This metric calculates expected net income while accounting for margin erosion due to rising costs; therefore, analyzing the future profit trajectory allows for the timely recognition of asset overvaluation risk before an actual decline in quotes.